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Abstract—The design of medical devices directly affects the
way healthcare practitioners carry out their daily tasks. Users
welcome design that takes into account the clinical environment,
in which the device is operated and is compatible with their
workflow. However, if the design fails to fit, the likelihood of
errors increases, which will put patient safety at risk. In this
paper, we report current practice related to UCD (User Centred
Design) in the context of medical device, focusing on end user
feedback mechanisms deployed in pre-market and post-market
phases of the device lifecycle. The results of an interview and
workshop study are reported, revealing shortcomings in current
feedback channels. In reaction to these shortcomings, we discuss
the advantages and feasibility of enabling automatic feedback
channel in medical device design, to ensure the quality and the
effectiveness of feedback.
I. INTRODUCTION
Amongst various interactive medical devices used in hospi-
tals, well-designed ones can be highly effective. But poorly
designed ones may challenge healthcare practitioners with
unexpected behaviour and low predictability. Design based
on assumptions and conducted in isolation of user feedback
may contribute to medical incident and cause catastrophic
consequences. UCD (User-Centred Design) has been in ex-
istence for decades, and appears in design and development
practice in various forms [1] [2]. It largely relies on end user
feedback, together with intuitive design, to ensure the quality
of design. It has been endorsed by international standards and
regulatory guidances, such as ISO 62366 and NPSA (National
Patient Safety Agency) Guidances, and appears to be making
an impact across the interactive device industry.
This paper addresses the difficulties for medical devices
stakeholders to effectively gather external feedback to apply
UCD, and hence suggests potential opportunities for improve-
ment. We analysed established feedback mechanisms, and
discuss the feasibility of implementing automatic feedback in
medical devices that allows adequate data of clinical use to be
gathered from appropriate channels. With the support of such
mechanism, medical device manufacturers may apply a set of
device-specific analysis algorithms to effectively flag design
flaws and inform future design.
II. FEEDBACK GATHERING AND USE IN MEDICAL DEVICE
LIFECYCLE
MHRA (the UK Medicines and Healthcare products Reg-
ulatory Agency) guidelines [3] argues that professional users
need to understand manufacturers’ intentions in order to be
able to use a device effectively and safely. While this is
reasonable, we argue that this misses a large part of the picture.
For many medical devices there is a gap between theory
(known to manufacturers) and practice (known to end users),
and often manufacturers design devices without understanding,
for example, how their interactive behaviour can increase the
likelihood of medical errors during situated use [4].
Theoretically, by gathering and analysing feedback, UCD
techniques help to optimise design around the needs, wants
and limitations of device users. These methods also allow
developers to foresee how users are likely to operate the device
and avoid assumptions that may not reflect the context of use.
As a result, the design provides better usability and safety.
However, current UCD practice in the medical context has
not kept up with UCD practitioners’ expectations. In fact, an
increase in the number and severity of infusion pump problems
has been seen over the years. Analysis of the FDA’s (Food
and Drug Administration) MDRs (Medical Device Report)
reveals many device problems that appear to be a result of
faulty design: for instance, between 2005–2009, over 56,000
MDRs were associated with the use of infusion pumps. Of
these reports, approximately 1% were reported as deaths, 34%
were reported as serious injuries, and 62% were reported
as malfunctions. Human factors (which include, but are not
limited to, use error) are one of the six frequently reported
problems. Subsequent root cause analyses revealed that many
of these design problems were foreseeable and, therefore, in
principle preventable [5].
To understand current UCD practice within the medical
device industry and how external feedback is gathered and
fed in to the design process, we carried out a series of semi-
structured interviews in 2010 [4]. Following this study, in
2011, we arranged further meetings and a series of workshops
to engage with a larger spectrum of medical device stakehold-
ers to continually explore some of the key issues. Of the 27
participants: 8 were from global medical device companies;
5 were from design houses or consulting companies; 4 were
from small medical device companies; 4 were with a NHS
Trust; 4 were regulators, evaluators or from testing labs; and
2 were from research labs.
A. Established Feedback Channels
Based on the study, we summarise the established feedback
channels into two phrases (pre-market and post-market), fur-
ther explained below.
1) Pre-Market User Engagement: Pre-market user engage-
ment is mainly carried out by the device manufacturer to-
wards fulfilling international standards, such as ISO 60601,
ISO 62366, ISO 62304. In the UK, guidance has been pro-
vided by the NPSA as part of the“Design for Patient Safety”
initiative [7], [8]. This supports UCD by detailing examples
of best practice and illustrating device specific issues and
recommendations. In America, the FDA also provides guid-
ance and suggested a series of UCD procedures to avoid Use
Hazards. Recommendations include: human factors evaluation,
summative human factors study, simulated use and clinical
evaluation. These resources, to some degree, have promoted
and sometimes urged the information flow between medical
device end users and manufacturers to assist UCD in the pre-
market phase.
Our interview participants were all aware of the need
for UCD, and have been using various UCD techniques to
gather and manage user input and feedback during the design
process. For example, some practitioners run focus groups
surrounding form factor issues. Scenarios are also a standard
technique, and sometimes used in conjunction with focus
groups or stakeholder workshops. Other commonly used meth-
ods include prototyping, cognitive walkthrough, interviews and
usability testing. Some participants were enabled, to some
extent, to work with people from other departments. Marketing
department was considered to be the major contact point to
the user. Thus, collaborative work between design teams and
marketing teams was valued.
2) Post-Market Surveillance: In the post-market phase,
feedback on safety is given higher priority than feedback
on usability. A great deal of feedback on device safety is
gathered through post-market safety monitoring and reporting,
supported by regulatory agencies.
MDR regulation requires the manufacturer to submit reports
to the FDA whenever they are aware of information that
reasonably suggests that a device they market may have caused
or contributed to a reportable death or serious injury, or has
malfunctioned and the malfunction would be likely to cause
or contribute to a reportable death or serious injury should it
recur.
Similarly, NPSA’s NRLS (National Reporting and Learning
System) collects confidential reports of patient safety incidents
from healthcare staff (across England and Wales) to be anal-
ysed by clinicians and safety experts. Based on the analysis,
safety alerts and guidance is produced for relevant bodies.
Parallel with NRLS, a formal mechanism is outlined in
the MDD (Medical Device Directive) and supported by the
MHRA, which logs adverse incidents as they happen with
devices. This system is open to reports from healthcare prac-
titioners, patients and medical device manufacturers. Informa-
tion gathered from reports will go through risk assessment
and, where appropriate, investigation undertaken by medical
device specialists. Results are distributed in various forms,
such as posters, One Liners and Device Bulletins. Stakeholders
involved in the report are updated continuously with the
progress. The MHRA would be involved in investigating
design alternatives if the conclusion revealed serious design
flaws.
Less formal mechanisms are deployed by medical device
manufacturers involving the use of call centres and training
staffs. Participants from international medical device compa-
nies spoke of conducting observations in client hospitals. If
there is a mismatch between the actual operating pattern and
the recommended routine, meetings would be arranged with
client’s representative to discuss potential solutions, which
usually involves re-training or re-configuration. However,
small medical device companies might not have the advantage
and resources to take such action.
B. Problems with Current Feedback Channels
Current feedback mechanisms have successfully provoked
better design of both medical devices software [9] and hard-
ware [10]. Based on data gathered through our study, an
overview of current feedback mechanisms in medical device
lifecycle is presented in Fig.1. The lifecycle consists of 13
phases, which are marked on arcs, with the input and output of
each phase shown as underlined text. Stakeholders are colour-
coded and marked on rings (where EBME stands for Electro-
Biomedical Engineering). Dark cells indicate stakeholders
involvement in each phase.
Our study reveals that there are a number of problems that
are in need of attention. These problems can be summarised
by seven groups.
1) Organisational Impact on UCD Practice: Some medical
device companies rely on outside consultants, usability engi-
neers or human factor experts, due to the benefits associated
with short term contracting. These external personnel are
responsible for proposing a design decision clarifying the
reasoning behind it. But it has to be accepted by the client.
Participants explained that some requests can not be fulfilled
because of other limits that the client is facing, stating:
“Sometimes the customer refuses to provide the
necessary resources, also due to some related
projects, it is very political. We have various
problems, most of them are related to the hierarchy
of the customer and the decision trees which are
rather huge.”
When a medical device development process involves sub-
contracting or outsourcing, getting access to end users could be
difficult. Participants explained that sometimes subcontractors
might not be allowed access to end users.
Fig. 1. An Overview of Feedback Mechanisms in Medical Device Lifecycle, Stakeholders Involved and Output Generated
2) Identifying the Right Source of Feedback: Because of the
complex nature of medical devices, and the fact that design can
involve multiple levels of outsourcing, it is crucial to identify
the right group of people to engage with and to prioritise
feedback.
Prioritising the competing demands of various stakeholder
groups was seen as a challenge and it could be difficult for
subcontractors or usability consultant to balance user needs
with those of the OEM (Original Equipment Manufacturer). In
addition, medical devices can be used by both clinicians and
patients. The requirements and feedback coming from these
two groups are often quite different.
3) Gaining Access to the Source of Feedback: Clinicians
are required to work long hours and with great intensity. A
union survey [13] has revealed that 80% of NHS staff reported
an increase workload over the year of 2010, and 77% increased
stress.
Participants expressed their concern about gaining access to
end users, stating:
“The user type determines how long you can have the
user for, or whether you can get the user at all. When
designing medical user interfaces, you can hardly get
hold of doctors or nurses, because they are just
busy.”
It is also reported that small medical device companies
struggle to gain access to end users due to low profile and lack
of resources. On the other hand, ethical hurdles are considered
barriers to all participants from industry regardless of their
company size:
“Going back to the ideal . . . if you can just go and talk
to people, see what they are really doing in the
hospital in the situation, that’s what you really want,
but you’ve got there barriers to go into these
situation, the ethical hurdles and so on.”
4) Missing Information on Real Clinical Situation: Tradi-
tional UCD techniques can not foresee the complexity of real
clinical situation. Though some factors can be controlled for
or investigated within a lab, the results from lab based studies
don’t always generalise to hospital settings due to the difficulty
of simulating or replicating a given context.
In 2003, a snapshot audit showed that in two main acute
hospitals in a South Wales NHS Trust, there were over 30 dif-
ferent infusion devices in use. Medical device standardisation
helped to bring the total number of different infusion devices
in use down to 8 [14] . However, infusion devices are only
one category of interactive medical device out of many that
nurses and doctors need to operate in a hospital environment!
The familiarity with these devices and their operating routines
would have an significant impact on the interaction speed and
accuracy:
“The more often the user interacts with the device, the
faster they get with it. And some times it’s difficult to
measure in lab based test where people are
unfamiliar with devices, because they interact more
slowly with it. If you press the button faster (than it
can respond), maybe nothing happens.”
Participants spoke of various means to compensate for the
deficiency of information on clinical situation. Some device
companies have clinical practitioners involved in the design
process or on the board, acting as Clinical User Surrogate
(See Fig. 1). Though they are not end users, they have an
understanding of what the end users will deal with in their
working environments. Such approaches are highly feasible
both financially and organisationally, but perhaps with limita-
tions.
5) Limitations of Trials and End User Evaluation Before
Deployment: Clinical trials and end user evaluation are ideal
approaches for feedback gathering, as it involves both real end
users and real clinical environment.
As shown in Fig.1, for some medical devices, clinical trial
could possibly be the first opportunity for the device to be
used in a realistic clinical situation prior to the market. In
other words, the trial could be the first stage when a real end
user is actually involved. However, participants explained that
by the time a product got to clinical trials, sufficient costs
had accumulated such that failure was not an option. User
tests at this stage would be designed to maximise the chance
of getting through the trail. Such trials are structured for
regulatory approval, rather than user evaluation and feedback
gathering.
In the post-market phase, medical devices may be evaluated
by medical device evaluators (e.g., Cedar, SMTL-Surgical
Medial devices Test Lab) that report to regulatory bodies (e.g.,
MHRA). Some NHS Trusts may contract external organisa-
tions to conduct test and evaluation, while others are tested
and evaluated using the Trust’s own EBME team.
Participants reported that though the test and evaluation
can generate a large amount of information for feedback, the
feedback channel between EBME and designer is rather weak.
Fig.1 shows a clear divide between phases where these two
parties are involved in. Though participants spoke of rare cases
where good communication between designers and EBME
staffs led to a significant improvement in the design of medical
devices, due to geographic limitations and organisational im-
pact, sales representatives are often the only contact they can
approach, and there is rarely formal acknowledgement from
the designer on the reception of such information:
“Very little formal feedback. You might get an
acknowledgement from the rep (representative) or
something like that. But you wouldn’t, once the
information is passed on to them, you would not,
generally, tend to get anything. You certainly wouldn’t
get how they would apply, what they’ve done.”
Prior to purchase and deployment, NHS Trusts policy and
procedures demand thorough evaluation of devices [15] [16].
Devices that meet procurement criteria can be arranged to
come into the Trust for end user evaluation. However, par-
ticipants spoke of situations where users have been trained on
legacy products and may experience difficulties in transferring
to new products. If a new product has a similar appearance
to the legacy product, though they may function differently,
nurses may assume that devices that look alike should behave
alike. That can influence the user’s perception of new devices,
and have an impact on the evaluation result.
The lack of time to gather adequate data from end user
evaluation is also raised. As mentioned previously, nurses
need to interact with large numbers of devices daily. The total
amount of time allocated on a new device during the evaluation
period is typically limited.
6) Under-reporting: Participants from regulatory agencies
explained that without stakeholders reporting, they wouldn’t
be aware of an incident, therefore, cannot take further action.
On the other hand, Sari et al [11] evaluated the relative
performance of a local routing incident reporting system
that feeds into NRLS. They found that though the reviewers
were specially trained and inter-rater reliability was good, the
implemented routine reporting system missed most patient
safety incidents identified by case note review, and detected
only 5% of those incidents that resulted in patient harm.
In addition, relying on users to report all incidents is flawed,
as evidence shows that users may not be aware of so-called
“unremarkable errors” [12], or understand whether certain
incidents (near misses) should be reported, often record limited
details about the event and often do not record the identity of
the device that was being used at the time.
7) Limitations of Current Logs: When applicable, interac-
tive medical devices record event logs (Fig. 1, Maintenance
phase and Safety Advice and Vigilance Phase). Such logs
can be used either for routine monitoring or for helping
retrospective analysis of known errors. In the majority of cases,
these logs are used for maintenance purposes or as a resource
in finding out the reason behind a failure in execution or an
incident. However, the difficulty of analysing logs is raised.
Currently, logs are processed and presented at a level of
abstraction rather than at a level of detailed user interaction,
and are rarely used until something fails. In complex software,
for which most of current research is based, it has been
necessary to do this in order to reduce the amount of data
logged. However, this process of abstraction eliminates im-
portant information on usability. The manufacturers of devices
do not normally provide tools to analyse logs on an usability
evaluation level. In some cases, it is reported that not all logs
are sequential, which makes exploring the user behavioural
pattern extremely challenging.
III. ENABLE FEEDBACK IN MEDICAL DEVICE SOFTWARE
DESIGN
Our study reveals the challenges faced by UCD practitioners
in incorporating feedback relating to the likely users and
usage of devices. Post-market feedback is mainly triggered by
adverse incidents that have already involved death or injury.
And studies have found that user errors are often under-
reported [17]. On the other hand, traditional UCD techniques
cannot effectively help designers foresee the complexity of
clinical situations in the premarket phase of the medical
device lifecycle. Fig.1 shows that it’s rarely the case when the
clinical user and the UCD practitioner are both involved in
the same phase, which makes it challenging for both parties
to participant in the establishment of an effective feedback
channel. However, it also shows that a large amount of clinical
usage and usability information is recorded as device logs,
which can potentially be used to inform future design.
Logs derived from user interface events have long been
viewed as a source for assessing the usability of an interactive
system [18]. Hilbert and Redmiles [19] describe an agent-
based approach to identify and report back when there is a
mismatch between actual usage and usage expectation. How-
ever, in general, the majority of modern commercial software
and safety critical systems only use event logs as a resource for
debugging or investigation. Unfortunately, interactive medical
devices have also fallen into this model.
The problem with this model is that it is usually too late to
prevent the error. When software crashes, it is not uncommon
to be presented with a dialog box that requests the user to
send some contextual logging information to the manufacturer
about the crash. Similarly, black-box and medical device logs
are generally ignored until something bad happens.
Interactive medical device logs should be carefully designed
so usability information can be continuously gathered and
periodically analysed. Periodical analysis of logs complements
Reason’s “Swiss Cheese” model [20] where latent errors
are not merely blocked but have a higher chance of being
discovered, acted upon and fixed.
Though medical device log is just one source of feedback
that can be improved and cannot solve all the problems, along
with appropriate analysing algorithms, a redesigned and well-
integrated logging system can bridge the gap between designer
and developer with more accurate feedback on clinical use.
IV. CONCLUSIONS
A large range of medical device stakeholders have supported
our study by sharing their valuable insights and rich work
experiences through interviews, meetings, visits and work-
shops. The study reveals that current feedback mechanisms in
medical device UCD are in need of further tuning. Although
the presence of post-marketing surveillance and Corrective
And Preventative Action (CAPA) makes developers aware
of problems, there is potential for a closer examination of
differences between assumed and actual usage.
It is clear that data on device usage should be gathered
automatically via improved software design. We have al-
ready demonstrated that by applying appropriate analysing
algorithms to logs from 58 infusion pumps, the mismatches
between design and real clinical practice can be identified
[21]. However, since device logs are device specific and not
currently standardised, the data to log and corresponding
analysing algorithm should be further designed. In addition,
automatically gathered data needs to be ready for secondary
use. Adequate IT infrastructure is needed to collect, transmit
and store the data to centralised databases for further analysis
and results communicated to the entire health system.
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